<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain><z:hpo ids='HP_0004831'>Recurrent thromboembolism</z:hpo> despite oral anticoagulation is primarily suspicious of overt or occult <z:hpo ids='HP_0002664'>neoplasia</z:hpo> </plain></SENT>
<SENT sid="1" pm="."><plain>We report on a man (age: 67 years) who presented with severe <z:hpo ids='HP_0100724'>thrombophilia</z:hpo> which was only controlled when the patient was set on a combined anticoagulation with low molecular weight <z:chebi fb="5" ids="28304">heparin</z:chebi> in supratherapeutic dosage and <z:chebi fb="0" ids="50438">phenprocoumon</z:chebi> with a target INR of 2.0 </plain></SENT>
<SENT sid="2" pm="."><plain>Despite repeated evaluation over about two years, a <z:e sem="disease" ids="C0006826" disease_type="Neoplastic Process" abbrv="">malignant tumour</z:e> could never be demonstrated </plain></SENT>
<SENT sid="3" pm="."><plain>However, the patient suffered in addition to a <z:e sem="disease" ids="C0242666" disease_type="Disease or Syndrome" abbrv="">protein S deficiency</z:e> from an antiphosphospholipid syndrome and a <z:hpo ids='HP_0011010'>chronic</z:hpo> <z:mpath ids='MPATH_501'>myelomonocytic leukaemia</z:mpath> </plain></SENT>
<SENT sid="4" pm="."><plain>We postulate that the accepted strong thrombogenicity of antiphosphospholipid syndrome was further increased by <z:e sem="disease" ids="C0242666" disease_type="Disease or Syndrome" abbrv="">protein S deficiency</z:e> and a possibly procoagulatory effect of the abnormal monocytes explaining the severe <z:hpo ids='HP_0100724'>thrombophilia</z:hpo> resistant to standard therapeutic anticoagulation with a <z:chebi fb="6" ids="28384">vitamin K</z:chebi> <z:chebi fb="68" ids="48706">antagonist</z:chebi> and usual therapeutic doses of low molecular weight <z:chebi fb="5" ids="28304">heparin</z:chebi>, respectively </plain></SENT>
</text></document>